China NMPA Grants IND Clearance to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate CancerJune 8, 2026
U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX‑0405 STEAP1 ADC for Gastric CancerJuly 8, 2025
Adcentrx Therapeutics Granted Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical CancerMay 6, 2025
Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025April 23, 2025
Adcentrx Therapeutics to Showcase Novel STEAP1 and NaPi2b ADCs with Oral and Poster Presentations at AACR 2025March 25, 2025
Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid TumorsJanuary 6, 2025
Adcentrx Therapeutics Doses First Patient in Phase 1b Expansion Cohorts with ADRX-0706 Nectin-4 ADCDecember 2, 2024
Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0405, a Potential First-in-Class ADC Targeting STEAP1 for the Treatment of Advanced Solid TumorsOctober 21, 2024
Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid TumorsMay 6, 2024
